
Please try another search
Investing.com - Constellation Pharmaceuticals jumped on Wednesday after a favorable preliminary Phase 2 clinical trial for a drug treatment for patients with Myelofibrosis.
All four patients achieved at least a 35% reduction in spleen volume and at least a 50% improvement in total symptom score as early as three months after treatment, the study showed.
The drug, called MANIFEST, is expected to end its primary testing period in August 2021.
Shares of Constellation Pharmaceuticals (NASDAQ:CNST) surged nearly 112% in midday trade.
By Hadeel Al Sayegh DUBAI (Reuters) -State oil giant Saudi Aramco (TADAWUL:2222) reported a soaring 90% rise in second-quarter profit on Sunday, beating analyst expectations and...
(Reuters) - Scandinavian airline SAS said on Saturday it entered into an agreement with Apollo Global Management (NYSE:APO) to raise $700 million of fresh financing it needs to...
(Reuters) -Anshu Jain, a top finance executive best known for helping German lender Deutsche Bank AG (NYSE:DB) take on the largest Wall Street firms, died overnight on Saturday...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.